Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Bio Explores Buyout To Boost Generics Platform
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen Announces Reverse Stock Split
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% – Time to Sell?
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Head-To-Head Analysis: Tevogen Bio (TVGN) and The Competition
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected